1062161-90-3

Basic information

• Product Name: WYE-687
• Synonyms: WYE-687;N-[4-[4-(4-Morpholinyl)-1-[1-(3-pyridinylmethyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]carbamic acid methyl ester;methyl 4-(4-morpholino-1-(1-(pyridin-3-ylmethyl)piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)phenylcarbamate;methyl N-[4-[4-morpholin-4-yl-1-[1-(pyridin-3-ylmethyl)piperidin-4-yl]pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]carbamate
• CAS NO: 1062161-90-3
• Molecular Formula: C₂₈H₃₂N₈O₃
• Molecular Weight: 528.60548
• Product Categories: PI3K/Akt/mTOR;Inhibitors;Akt;mTOR;PI3K
• Mol File: 1062161-90-3.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Density: 1.40
• Solubility: insoluble in H2O; insoluble in EtOH; insoluble in DMSO
• PKA: 13.42±0.70(Predicted)
• CAS DataBase Reference: WYE-687(CAS DataBase Reference)
• NIST Chemistry Reference: WYE-687(1062161-90-3)
• EPA Substance Registry System: WYE-687(1062161-90-3)

Safety Data

• Hazardous Substances Data: 1062161-90-3(Hazardous Substances Data)

Usage

Description

WYE-687 is an ATP-competitive and selective inhibitor of mammalian target of rapamycin (mTOR), a protein that plays a crucial role in cell growth, proliferation, and survival. It has been studied for its potential therapeutic applications in various cancer types.
Used in Oncology:
WYE-687 is used as an inhibitor for mTOR, which is a key protein involved in cell growth and proliferation. It has been shown to be effective in overcoming resistance to mTOR kinase inhibitors (mTorKIs) in patients with renal cell carcinoma or colorectal cancer when used in combination with Ras-Raf-MEK1/2 inhibitors. This combination therapy may enhance the efficacy of treatment and improve patient outcomes.

Biological Activity

wye-687 is an atp-competitive inhibitor of mtor with ic50 value of 7nm [1].wye-687 is a small-molecule pyrazolopyrimidine inhibitor of mtor1 and mtor2. in the immune-complex kinase assay using his6-akt and his6-s6k as the specific substrates of mtor1 and mtor2, wye-687 prevents mtor from phosphorylating the substrates dose-dependently. besides that, wye-687 is found to highly selective against pi3kα (>100-fold) and pi3kγ (>500-fold) as well as 24 other protein kinases. it is found that wye-687 can suppress cell growth via causing a strong g1 arrest in cell cycle in tumor cell lines including mda361 and hct116. wye-687 also affects the angiogenic factor of cancer cells. it reduces the expression of hif-1α in u87mg, mda361 and lncap cells [1].

references

[1] yu k, toral-barza l, shi c, et al. biochemical, cellular, and in vivo activity of novel atp-competitive and selective inhibitors of the mammalian target of rapamycin. cancer research, 2009, 69(15): 6232-6240.

Upstream product

• 67-56-1 methanol 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 1198178-29-8 4-(4-morpholino-1-(1-(pyridin-3-ylmethyl)piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)aniline hydrochloride 

Downstream Products

• 1198178-23-2 WYE-687 hydrochloride 

Relevant articles and documents

ATP-competitive inhibitors of the mammalian target of rapamycin: Design and synthesis of highly potent and selective pyrazolopyrimidines

The mammalian target of rapamycin (mTOR), a central regulator of growth, survival, and metabolism, is a validated target for cancer therapy. Rapamycin and its analogues, allosteric inhibitors of mTOR, only partially inhibit one mTOR protein complex. ATP-competitive, global inhibitors of mTOR that have the potential for enhanced anticancer efficacy are described. Structural features leading to potency and selectivity were identified and refined leading to compounds with in vivo efficacy in tumor xenograft models.